Malenka Robert C.
CIK: 0002021198
Associated companies
Transaction History
| MPLT | ▼ Sell | Open Market | 8,593 | $231K | 4/15/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 736 | $13K | 2/24/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 10,788 | $198K | 2/23/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 476 | $9K | 2/23/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 2,195 | $40K | 2/20/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 12,116 | $221K | 2/13/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 241 | $4K | 2/11/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 6,622 | $120K | 2/10/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 1 | $18 | 2/3/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 7,039 | $127K | 2/2/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 6,612 | $120K | 1/30/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 21,262 | $394K | 1/29/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 5,860 | $109K | 1/28/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 664 | $13K | 1/28/2026 | View on chart |
| MPLT | ▼ Sell | Other | 3,895 | — | 10/28/2025 | View on chart |
| MPLT | ▲ Buy | Grant | 34,390 | $0 | 10/27/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
MapLight Therapeutics Shares Fall 34.8% in Four Weeks
MapLight Therapeutics stock has dropped 34.8% over the past month, leading some market observers to discuss potential for a turnaround. The decline places the stock near its 52-week low of $8.70, while the current RSI of 21.9 suggests the shares are in oversold territory. Analysts maintain an average price target of $26.54, indicating a wide range of expectations for the company's future performance.
MapLight Therapeutics Shares Fall 34.8% in Four Weeks. MapLight Therapeutics stock has dropped 34.8% over the past month, leading some market observers to discuss potential for a turnaround. The decline places the stock near its 52-week low of $8.70, while the current RSI of 21.9 suggests the shares are in oversold territory. Analysts maintain an average price target of $26.54, indicating a wide range of expectations for the company's future performance.